Sephience Sales Momentum Prompts Citi to Upgrade PTC Therapeutics to Buy
Citi turns bullish on PTCT, citing strong Sephience sales in PKU and potential $1B+ peak, raising target to $108.
/ 124 items
#XY Analyst Up/Down↓
Oppenheimer Launches Coverage on DTIL with Outperform Rating – 100%+ Upside Ahead?
Oppenheimer rates DTIL “Outperform” ($20). ARCUS gene editing shows promise in DMD & Hep B with big upside potential.
Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential
COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech.
Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
Wells Fargo Boosts Oscar Health Rating as Exchange Outlook Improves
Wells Fargo upgraded Oscar Health, citing a better 2026 outlook, improving costs, and stronger-than-expected enrollment.